Osteonic오스테오닉

Osteonic's revenue and profit have grown strongly over several years, but its shares have fallen about 42% over the past year.

Osteonic, a Korean maker of bone implants, reported trailing twelve-month revenue of ₩51.0B and net income of ₩10.2B to H1 2026, with an operating margin of 18.4%. Its share price of ₩4,295 sits well below its 52-week high of ₩7,740, and the data shows a trailing P/E of 8.7 and P/B of 1.2. The filings show recent routine governance activity, including a shareholders' meeting, amended reports and 5%+ holding reports.

What stands out

• Revenue rose from ₩15.6B in 2021 to ₩45.4B in 2025, with 2025 growth of 32.6%.
• Trailing free cash flow is negative at about -₩0.6B, even though reported net income is positive.
• Net income is higher than operating income on a trailing basis, which the data does not explain.
• Borrowings of ₩24.1B exceed cash of ₩14.3B, and liabilities are 57.8% of equity.
• Foreign ownership eased from 6.8% to 6.3% over the last 60 days, and institutions were net sellers over the past 20 days.

What to watch

• The amended half-year report filed on 29 September 2026 and any further changes to reported figures.
• Upcoming quarterly results and whether free cash flow turns positive given the debt level.
• No news headlines are in the data, so the reasons for the share price decline are not stated.